Fundraising Fox

Alek Safarian

Investor

CEO at ALSA Ventures

New York, New York, United States

FoundedVantage Biosciences

About

A pharmacist with over thirty years in drug development, Alek worked in regulatory and clinical research roles across the Asia-Pacific and founded the Sydney-based CRO Novotech. He holds a BPharm and MBA from the University of Sydney.

Experience

  1. ALSA VenturesCEOcurrent2018 β€” presentLondon Area, United Kingdom
  2. NovotechMember of the Board of Directors1996 β€” 2017
  3. NovotechCEO1996 β€” 2017
  4. Marion Merrell Dow (now Sanofi-Aventis)Head, Scientific Affairs, Asia-Pacific1990 β€” 1995
  5. Ciba-Geigy (now Novartis)Regulatory Affairs Associate1988 β€” 1990

Education

  1. University of SydneyMBA, Business Administration1993 β€” 1995
  2. University of SydneyB.Pharm., Pharmacy1984 β€” 1986
  3. St. Benedict's Grammar School1978 β€” 1982

Skills & more

Clinical Trials31Regulatory Affairs13Clinical Development13Medical Devices2Biotechnology20Informatics2Medical Writing4Clinical Research8Mergers & Acquisitions1Infectious Diseases3Pharmacovigilance3Diabetes2
+9 moreVaccinesGCPOncologySopSOPCTMSCROPharmaceutical IndustryStrategy

Languages Armenian Β· English

  • University of Sydney Campaign Ambassador β€” University of Sydney

From Alek's professional profile.

Same school

Shared employers

Colleagues at ALSA Ventures

Network32

β–Ά20 more connections

Barbara SchilbergBiao HeCharline GauthierClay WhiteheadCobih ObihCody AndersonDarius CheungDavis OkothDelia FlanaganDmytro DvurechenskyiDoug WilstermanEduardo ChadesEmily WangErik SchmidtEugene WeiFaisal AloufiiFrancesca BertocchiGilad NovickGladys NunezTerence Leahy

Investors connected to Alek in public investor directories β€” a warm-intro map.